natgillin/translations-raw huggingface dataset:
Therapeutic agents useful for treating pain 
TERAPEUTSKI AGENSI KORISNI ZA LIJEČENJE BOLI
MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS 
MAKROCIKLIČKI INHIBITORI VIRUSA HEPATITISA C
CYCLOPEPTIDE DERIVATIVES WITH ANTI-INTEGRIN ACTIVITY 
CIKLOPEPTIDNI DERIVATI SA ANTI-INTEGRINSKOM AKTIVNOŠĆU
Tamper-resistant products for opioid delivery 
PROIZVODI OTPORNI NA MIJEŠANJE ZA OPIOIDNU PRIMJENU
INSULINOTROPIC PEPTIDE SYNTHESIS 
SINTEZA INZULINOTROPNOG PEPTIDA
COMPACT FLUORESCENT LAMP 
KOMPAKTNA FLUOROSCENTNA ŽARULJA
PROGESTERONE RECEPTOR ANTAGONISTS 
ANTAGONISTI RECEPTORA PROGESTERONA
Process for the removal of endocrine disrupting compounds 
POSTUPAK ZA UKLANJANJE SPOJEVA ENDOKRINE RAZGRADNJE
THERAPEUTIC HUMANISED ANTIBODIES AGAINST CD45 ISOFORMS 
TERAPEUTSKA HUMANIZIRANA ANTITIJELA PROTIV CD45-IZOFORMA
PROCESS FOR PRODUCING BOX STRUCTURES FOR FRAMES FOR DISAPPEARING SLIDING DOORS 
POSTUPAK PROIZVODNJE STRUKTURA U OBLIKU KUTIJA ZA OKVIRE ZA KLIZNA VRATA KOJA NESTAJU
NEW COMBINATIONS OF A 5-HT3 RECEPTOR ANTAGONIST WITH RACECADOTRIL OR DEXECADOTRIL 
NOVE KOMBINACIJE ANTAGONISTA RECEPTORA 5-HT3 S RACEKATODRILOM ILI DEKSEKATODRILOM
FACTOR VII OR VIIA GLA DOMAIN VARIANTS 
VARIJANTE GLA DOMENE FAKTORA VII ILI VIIA
DEMUCILAGED FLAX SPROUTS AND THEIR BY-PRODUCT AS WELL AS PRODUCTION AND APPLICATION THEREOF 
KLICE LANA BEZ SADRŽAJA SLUZI I NJIHOV NUSPROIZVOD, KAO I NJIHOVA PROIZVODNJA I PRIMJENA
Purine derivatives as adenosine A1 receptor agonists and methods of use thereof 
DERIVATI PURINA KAO AGONISTI ADENOZIN A1 RECEPTORA I POSTUPCI ZA NJIHOVU UPORABU
SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE 
SUMPORNI SPOJEVI KAO INHIBITORI SERINSKE PROTEAZE NS3 VIRUSA HEPATITISA C
METHOD FOR THE DETECTION OF EGFR MUTATIONS IN BLOOD SAMPLES 
POSTUPAK DETEKCIJE MUTACIJA EGFR U UZORCIMA KRVI
-(AMINO-SUBSTITUTED)-4-ARYL PYRAMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES 
-(AMINO-SUPSTITUIRANI)-4-ARIL PIRAMIDINI I SRODNI SPOJEVI KORISNI ZA LIJEČENJE INFLAMATORNIH BOLESTI
PROCESS FOR THE PREPARATION OF CARVEDILOL AND ITS ENANTIOMERS 
POSTUPAK ZA PRIPREMU KARVEDILOLA I NJEGOVIH ENANTIOMERA
DATA TRANSMISSION 
PRIJENOS PODATAKA
Process for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole. 
MEĐUPRODUKTI U DOBIVANJU trans-5-KLOR-2-METIL-2,3,3a,12b-TETRAHIDRO-1H-DIBENZ[2,3:6,7]OKSEPINO[4,5-C]PIROLA
Control system of an electric motor for surgical applications 
UPRAVLJAČKI SUSTAV ELEKTROMOTORA ZA KIRURŠKE PRIMJENE
Compounds with anti-inflammatory activity 
MAKROLIDNI KONJUGATI S PROTUUPALNOM AKTIVNOŠĆU
method of preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate 
KRISTALINIČNI OBLICI (R)-8-KLORO-1-METIL-2,3,4,5-TETRAHIDRO-1H-3-BENZAZEPIN HIDROKLORIDA
CRYSTALLINE FORMS OF A BIPHENYL COMPOUND 
KRISTALNI OBLICI BIFENILNOG SPOJA
HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 
HETEROCIKLIČKI SUPSTITUIRANI FENIL METANONI KAO INHIBITORI GLICIN TRANSPORTERA 1
BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS 
DERIVATI BENZOKINAZOLINA I NJIHOVA UPORABA U LIJEČENJU BOLESTI KOSTI
Locking nail system for arthrodesis reconstruction in calcaneus fractures 
SUSTAV ČAVLA SA ZAKLJUČAVANJEM ZA REKONSTRUKCIJU FRAKTURA KALKANEUSA ARTRODEZOM
Methods for improving bioavailability of a renin inhibitor 
POSTUPCI ZA POBOLJŠANJE BIORASPOLOŽIVOSTI INHIBITORA RENINA
Method and system for detecting the phase wiring of an unknown phase voltage relative to a reference phase voltage 
POSTUPAK I SUSTAV ZA DETEKCIJU FAZNOG VODIČA NEPOZNATOG FAZNOG NAPONA U ODNOSU PREMA REFERENTNOM FAZNOM NAPONU
INHIBITORS OF AKT (PROTEIN KINASE B) 
INHIBITORI PROTEINA AKT (PROTEIN KINAZA B)
HCV NS-3 SERINE PROTEASE INHIBITORS 
INHIBITORI HCV NS-3 SERIN PROTEAZE
USE OF A HYDROPHILIC MATRIX COMPRISING A POLYACRYLIC ACID DERIVATIVE, A CELLULOSE ETHER AND A DISINTEGRANT FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING FEMALE GENITAL DISORDERS 
UPOTREBA HIDROFILNOG MATRIKSA KOJI SE SASTOJI OD DERIVATA POLIAKRILNE KISELINE, CELULOZNOG ETERA I SREDSTVA ZA RASPADANJE U PROIZVODNJI MEDIKAMENTA ZA LIJEČENJE ŽENSKIH GENITALNIH POREMEĆAJA
PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS 
POSTUPAK ZA PRIPREMU 2-AMINOTIAZOL-5-AROMATIČNIH KARBOKSAMIDA KAO INHIBITORA KINAZE
PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES 
POSTUPAK PRIPRAVE DERIVATA TETRAZOLA OD ORGANSKIH BOR I ORGANSKIH ALUMINIJ AZIDA
Method for cold forging high strength fastener from austenitic 300 series material 
POSTUPAK HLADNOG KOVANJA VIJAKA VISOKE ČVRSTOĆE IZ MATERIJALA AUSTENIT SERIJE 300
PROCESS AND INSTALLATION FOR INCREASING THE BURNING ENERGY PRODUCED BY A NATURAL FUEL GAS 
POSTUPAK I POSTROJENJE ZA POVEĆANJE ENERGIJE IZGARANJA DOBIVENE OD PRIRODNOG PLINA
PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS 
PERIKONDENZIRANI TRICIKLIČKI SPOJEVI, KORISNI KAO ANTIBAKTERIJSKA SREDSTVA
PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES 
DERIVATI PIPERAZINILA KORISNI U LIJEČENJU BOLESTI POSREDOVANIH RECEPTOROM GPR38
MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES 
MIKROČESTICE KOJE SADRŽE ANALOGE SOMATOSTATINA
FORMULATIONS FOR BENZIMIDAZOLYL PYRIDYL ETHERS 
FORMULACIJE ZA BENZIMIDAZOLIL PIRIDIL ETERE
HIV INTEGRASE INHIBITORS 
INHIBITORI HIV INTEGRAZE
High throughput assay of LP-PLA2 activity 
VISOKO PROTOČNO ISPITIVANJE AKTIVNOSTI LP-PLA2
INJECTION APPARATUS HAVING A NEEDLE CASSETTE FOR DELIVERING A PHARMACEUTICAL LIQUID 
INJEKCIJSKA APARATURA KOJA IMA KAZETU ZA IGLE ZA DAVANJE FARMACEUTSKE TEKUĆINE
MODIFIED ADENOVIRUS HEXON PROTEIN AND USES THEREOF 
MODIFICIRANI HEKSON PROTEIN ADENOVIRUSA I NJEGOVE UPORABE
POLYPEPTIDES HAVING ANTIMICROBIAL ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME 
POLIPEPTIDI KOJI IMAJU ANTIMIKROBNO DJELOVANJE I POLINUKLEOTIDI KOJI IH KODIRAJU
PHARMACEUTICAL COMPOSITION COMPRISING SIMVASTATIN AND EZETIMIBE 
FARMACEUTSKI PRIPRAVAK KOJI SADRŽAVA SIMVASTATIN I EZETIMIB
CD20 ANTIBODIES WITH INCREASED FC RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION 
CD20 ANTITIJELA S POVEĆANIM AFINITETOM VEZIVANJA FC RECEPTORA I EFEKTORSKIM DJELOVANJEM
Pharmaceutical compositions of a neuroactive steroid and uses thereof 
FARMACEUTSKI SASTAVI NEUROAKTIVNOG STEROIDA I NJIHOVA UPORABA
BENZIMIDAZOLE COMPOUNDS 
SPOJEVI BENZIMIDAZOLA
MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESS 
MODULATORI AKTIVNOSTI KEMOKINSKIH RECEPTORA, KRISTALNI OBLICI I POSTUPCI
TUBERCULOSIS VACCINE WITH IMPROVED EFFICACY 
CJEPIVO PROTIV TUBERKULOZE POBOLJŠANE UČINKOVITOSTI
Stable pharmaceutical formulations of montelukast sodium 
STABILNE FARMACEUSTKE FORMULACIJE MONTELUKAST NATRIJA
CLOSING SYSTEM FOR DOOR AND WINDOW CASINGS AND CASING COMPRISING THIS CLOSING SYSTEM 
SUSTAV ZA ZATVARANJE KUĆIŠTA ZA VRATA I PROZORE I KUĆIŠTE KOJE SADRŽI TAJ SUSTAV ZA ZATVARANJE
GYROSCOPIC APPARATUS 
ŽIROSKOPSKI APARAT
HUMANIZED ANTI-CMET ANTAGONISTS 
HUMANIZIRANI ANTI-CMET ANTAGONISTI
INTRANASAL COMPOSITIONS 
INTRANAZALNE KOMPOZICIJE
MALEATE SALTS OF A QUINAZOLINE DERIVATIVE USEFUL AS AN ANTIANGIOGENIC AGENT 
MALEATNE SOLI DERIVATA KINAZOLINA KORISNE KAO ANTIANGIOGENO SREDSTVO
Apparatus for transmitting and receiving a signal and method of transmitting and receiving a signal 
UREĐAJI ZA PRIJENOS I PRIMANJE SIGNALA I POSTUPAK ZA PRIJENOS I PRIMANJE SIGNALA
Combinations comprising antimuscarinic agents and PDE4 inhibitors 
KOMBINACIJE KOJE SADRŽE ANTIMUSKARINSKA SREDSTVA I PDE4 INHIBITORE
CHEMICAL COMPOUNDS 
KEMIJSKI SPOJEVI
A media system and method 
MEDIJSKI SUSTAV I POSTUPAK
OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS 
ILI 4-MONOSUPSTITUIRANI FENOLSKI I TIOFENOLSKI DERIVATI, KORISNI KAO H3 LIGANDI
Monoclonal antibodies to hepatocyte growth factor 
MONOKLONSKA ANTITIJELA PROTIV ČIMBENIKA RASTA HEPATOCITA
DPP IV INHIBITOR FORMULATIONS 
FORMULACIJE INHIBITORA DPP IV
TRANSDERMAL STEROID FORMULATION 
TRANSDERMALNA FORMULACIJA STEROIDA
-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS 
-ANILINOKVINOLIN-3-KARBOKSAMIDI KAO INHIBITORI CSF-1R KINAZE
DIRECT DETERMINATION OF VITAMIN D IN SERUM OR PLASMA 
IZRAVNO ODREĐIVANJE VITAMINA D U SERUMU ILI PLAZMI
DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES 
DERIVATI DIHIDROPIRAZOLOPIRIMIDINONA
PYRIDOOXAZEPINE PROGESTERON RECEPTOR MODULATORS 
PIRIDOOKSAZEPINSKI MODULATORI PROGESTERONSKOG RECEPTORA
PEPTIDES WHICH CAN BIND TO TRANSFORMING GROWTH FACTOR BETA 1 (TGF-BETA1) 
PEPTIDI KOJI SE MOGU VEZATI NA TRANSFORMIRAJUĆI ČIMBENIK RASTA BETA 1 (TGF-BETA 1)
Chemical in situ sulphonating process 
KEMIJSKI IN SITU POSTUPAK SULFONIRANJA
CONTAINER FOR STORING AND UNLOADING BULK MATERIAL 
SPREMNIK ZA SKLADIŠTENJE I ISTOVAR RASUTOG MATERIJALA
COMBINED USE OF EXTERNAL AND INTERNAL SOLVENTS IN PROCESSING GASES CONTAINING LIGHT MEDIUM AND HEAVY COMPONENTS 
KOMBINIRANO KORIŠTENJE VANJSKIH I UNUTARNJIH OTAPALA U PROCESNIM PLINOVIMA KOJI SADRŽE LAKE, SREDNJE I TEŠKE KOMPONENTE
SUBSTITUTED SPIROBENZAZEPINES 
SUPSTITUIRANI SPIROBENZAZEPINI
PRODUCTION OF A TNFR-IG FUSION PROTEIN 
POSTUPAK ZA PROIZVODNJU TNFR-IG FUZIJSKOG PROTEINA
CHEMICAL PROCESS 
KEMIJSKI POSTUPAK
Valsartan formulations 
FORMULACIJE S VALSARTANOM
PROCESS FOR THE PREPARATION OF A BIOMIMETIC BONE SUBSTITUTE AND ITS USES 
POSTUPAK ZA PRIPREMU BIOMIMETIČKE ZAMJENE ZA KOST I NJEGOVE PRIMJENE
EXO- AND DIASTEREO- SELECTIVE SYNTHESES OF HIMBACINE ANALOGS 
EGZO- I DIJASTEREOSELEKTIVNA SINTEZA ANALOGA HIMBACINA
GABOXADOL FOR TREATING DEPRESSION AND OTHER AFFECTIVE DISORDERS 
GABOKSADOL ZA LIJEČENJE DEPRESIJE I DRUGIH AFEKTIVNIH POREMEĆAJA
METHOD OF INDUCING RESISTANCE TO HARMFUL FUNGI 
POSTUPAK ZA INDUKCIJU OTPORNOSTI NA ŠTETNE GLJIVE
TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS 
SPOJEVI AMINOBENZOFENONA SUPSTITUIRANI TRIAZOLOM
Process and intermediate compounds useful in the preparation of statins, particularly rosuvastatin 
POSTUPAK I INTERMEDIJERNI SPOJEVI KORISNI ZA DOBIVANJE STATINA, NAROČITO ROSUVASTATINA
CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY 
CIKLIČKI DERIVATI KAO MODULATORI AKTIVNOSTI KEMOKINSKIH RECEPTORA
PHARMACEUTICAL COMPOSITIONS OF A NEUROACTIVE STEROID AND USEES THEREOF 
FARMACEUTSKI SASTAVI NEUROAKTIVNOG STEROIDA I NJIHOVA UPORABA
Pharmaceuticals compositions of a neuroactive steroid and uses thereof 
FARMACEUTSKI SASTAVI NEUROAKTIVNOG STEROIDA I NJIHOVA UPORABA
POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS 
POLIPEPTIDI ZA INDUKCIJU ZAŠTITNOG IMUNITETNOG ODGOVORA PROTIV STAPHYLOCOCCUS AUREUS
SCREWING/ROLLING HEAD FOR PRE-THREADED CAPS 
PRITEZNO/OKRETNA GLAVA ZA PRETHODNO NAMOTANE KAPICE
IMMUNOSTIMULATORY COMBINATION FOR THE PROPHYLACTICS AND TREATMENT OF HEPATITIS C 
IMUNOSTIMULATORNE KOMBINACIJE ZA PROFILAKSU I LIJEČENJE HEPATITISA C
MICROORGANISMS AS CARRIERS OF NUCLEOTIDE SEQUENCES CODING FOR ANTIGENS AND PROTEIN TOXINS, PROCESS OF MANUFACTURING AND USES THEREOF 
MIKROORGANIZMI KAO NOSAČI ŠIFRIRANJA NUKLEOTIDNIH ODSJEČAKA ZA ANTIGENE I PROTEINSKE TOKSINE, POSTUPAK NJIHOVE PRIPRAVE I NJIHOVA UPORABA
Antagonist anti-CD40 monoclonal antibodies and methods for their use 
ANTAGONISTI ANTI-CD-40 MONOKLONALNIH ANTITIJELA I METODE NJIHOVE UPOTREBE
AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS 
AMIDNI DERIVATI KOJI NOSE CIKLOPROPILAMINOKARBONILNI SUPSTITUENT KORISNI KAO INHIBITORI CITOKINA
PHARMACEUTICAL COMPOSITIONS COMPRISING IMATINIB AND A RELEASE RETARDANT 
FARMACEUTSKI SASTAVI KOJI SADRŽE IMATINIB I USPORIVAČ OTPUŠTANJA
SEMI-SOLID MUCOADHESIVE FORMULATIONS 
POLUČVRSTE MUKOADHEZIVNE FORMULACIJE
NOVEL FSH GLYCOSYLATION VARIANT D3N 
NOVA FSH GLIKOZILACIJSKA VARIJANTA D3N
ORALLY DISINTEGRATING COMPOSITION OF OLANZAPINE OR DONEPEZIL 
ORALNO DEZINTEGRIRAJUĆI PRIPRAVAK OLANZAPINA ILI DONEPEZILA
PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV 
POSTUPCI I INTERMEDIJERI ZA PRIPRAVU MAKROCIKLIČKOG INHIBITORA PROTEAZE ZA HCV
-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS 
-AMINOARILOKSAZOLNI SPOJEVI KAO INHIBITORI TIROZINSKE KINAZE
NEW AND GENTLE PROCESS FOR CONVERSION OF CYSTINE IN KERATIN-CONTAINING MATERIALS TO LANTHIONINE 
NOVI I BLAŽI PROCES ZA PRETVORBU CISTINA U KERATIN KOJI SADRŽI MATERIJALE ZA LANTIONIN
THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS 
TIAZOLPIRAZOLOPIRIMIDINI KAO ANTAGONISTI RECEPTORA CRF1
BORDEAUX MIXTURE SUSPENSION AND PROCESS FOR THE PREPARATION THEREOF 
SUSPENZIJA BORDEAUX MJEŠAVINE I POSTUPAK ZA PRIPREMU TOGA
MEDICAMENT FOR THE ENHANCEMENT OF COGNITIVE FUNCTION AND NEUROPROTECTION 
LIJEK ZA POBOLJŠANJE KOGNITIVNE FUNKCIJE I ZA NEUROZAŠTITU
INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 
INHIBITORI INTERAKCIJE IZMEĐU MDM2 I P53
BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C 
DERIVATI BIFENILA I NJIHOVA UPORABA ZA LIJEČENJE HEPATITISA C
HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS 
HETEROAROMATIČNI SPOJEVI HINOLINA I NJIHOVA UPORABA KAO PDE10 INHIBITORA
CHEMOKINE RECEPTOR ANTAGONISTS 
ANTAGONISTI KEMOKIN RECEPTORA
Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin 
AGONISTI BETA-2 ADRENOCEPTORA ZA LIJEČENJE KOŽNIH BOLESTI VEZIVNOG TKIVA
BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE 
DERIVATI BIFENILOKSIOCTENE KISELINE ZA LIJEČENJE RESPIRATORNIH BOLESTI
NEW STABLE HYPERBARIC COMPOSITION COMPRISING PRILOCAINE HCL, USE OF SAID NEW COMPOSITION FOR INTRATHECAL ANAESTHESIA, AND METHOD FOR MANUFACTURING SAID COMPOSITION 
NOVA STABILNA HIPERBARIČNA KOMPOZICIJA KOJA SADRŽI PRILOKAIN HCL, PRIMJENA NAVEDENE NOVE KOMPOZICIJE ZA INTRATEKALNU ANESTEZIJU I POSTUPAK ZA PROIZVODNJU NAVEDENE KOMPOZICIJE
VACUUM STERILIZATION PROCESS AND DEVICE 
POSTUPAK I UREĐAJ ZA VAKUUMSKU STERILIZACIJU
PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS 
PIRIDIN KARBOKSAMIDI KAO INHIBITORI 11-BETA-HSD1
O-SUBSTITUTED-DIBENZYL UREA-DERIVATIVES AS TRPV1 RECEPTOR ANTAGONISTS 
O-SUPSTITUIRANI DERIVATI DIBENZIL-UREE KAO ANTAGONISTI TRPV1 RECEPTORA
Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema 
LIJEČENJE NEOVASKULARNIH POREMEĆAJA OKA, POPUT MAKULARNE DEGENERACIJE, ANGIOIDNIH STRIJA, UVEITISA I EDEMA MAKULE
DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE 2 ADRENERGIC RECEPTOR 
DERIVATI 4-(2-AMINO-1-HIDROKSIETIL)FENOLA KAO AGONISTI ADRENERGIČKOG RECEPTORA 2
COMBINATION OF PYRIMIDYLAMINOBENZAMIDE COMPOUNDS AND IMATINIB FOR TREATING OR PREVENTING PROLIFERATIVE DISEASES 
SMJESA OD PIRIMIDILAMINOBENZAMID SPOJEVA I IMATINIBA ZA LIJEČENJE ILI PREVENCIJU PROLIFERATIVNIH BOLESTI
TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS 
TRICKLIČKI SPOJEVI S DUŠIKOM KAO ANTIBAKTERIJSKA SREDSTVA
PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) 
PIRIDINAMINOSULFONIL SUPSTITUIRANI BENZAMIDI KAO INHIBITORI CITOKROMA P450 3A4 (CYP3A4)
ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS 
ENANTIOMERNO ČISTI AMINOHETEROARILNI SPOJEVI KAO INHIBITORI PROTEINSKIH KINAZA
IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER 
IMIDAZOLIDINONILAMINOPIRIMIDINSKI SPOJEVI ZA LIJEČENJE RAKA
Equipment and process for continuously making stack packages of tiles or the like 
UREĐAJ I POSTUPAK ZA KONTINUIRANU IZRADU PAKETA NASLAGANIH PLOČICA ILI TOME SLIČNOG
Nipah virus vaccines 
CJEPIVO PROTIV NIPAH VIRUSA
PRODUCT FOR THE TREATMENT OF WASTEWATERS AND SEWAGE 
PRODUKTI ZA TRETMAN OTPADNIH VODA I KANALIZACIJSKOG OTPADA
GLP-1 PEGYLATED COMPOUNDS 
GLP-1 PEGILIRANI SPOJEVI
INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION 
INHIBITORI REPLIKACIJE VIRUSA HUMANE IMUNODEFICIJENCIJE
MACROLIDES WITH ANTI-INFLAMMATORY ACTIVITY 
MAKROLIDI S PROTUUPALNOM AKTIVNOŠĆU
O-substituted-dibenzyl urea- or thiourea- derivatives as trpv1 receptor antagonists 
O-SUPSTITUIRANI DERIVATI DIBENZIL-UREE KAO ANTAGONISTI TRPV1 RECEPTORA
A method for aging alcoholic liquids is dislcosed, which utilizes an esterification catalyst to esterify alcoholic liquids in supercritical carbon dioxide, so as to significantly reduce the time required for aging of alcoholic liquids. 
Postupak dozrijevanja alkoholne tekućine, u kojem se alkoholnu tekućinu esterificira u prisutnosti katalizatora esterifikacije, naznačen time što navedenu alkoholnu tekućinu se esterificira u superkritičnom ugljičnom dioksidu, kako bi se skratilo vrijeme potrebno za dozrijevanje alkoholne tekućine.
The present invention relates to a pharmaceutical composition, comprising 3a-hydroxy-3β-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one or a pharmaceutically-acceptable salt or solvate thereof, and one or more pharmaceutically-acceptable excipients, wherein the composition provides steady state plasma levels of 3a-hydroxy-3β-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 5 ng/mL to 500 ng/mL for a duration of from 6 h to 24 h following administration. 
Farmaceutski sastav za uporabu u liječenju depresije, bolesne potrebe za alkoholom i/ili ovisnosti o alkoholu, predmenstrualne napetosti, predmenstrualnog sindroma ili predmenstrualnog disforičnog poremećaja, naznačen time, da sadrži 3a-hidroksi-3 -metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-on ili njegovu farmaceutski prihvatljivu sol ili solvat i jedan ili više farmaceutski prihvatljivih ekscipijenata, kod čega sastav daje stacionarno stanje razine u plazmi 3a-hidroksi-3 -metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-ona u području od 5ng/ml do 500 ng/ml u trajanju od 12 h do 24 h nakon davanja.
The present invention relates to the removal of endocrine disrupting compounds from an aqueous medium by adding surface-reacted natural calcium carbonate or an aqueous suspension comprising surface-reacted calcium carbonate and having a pH greater than 6.0 measured at 20 °C, to the medium, wherein the surface-reacted calcium carbonate is a reaction product of natural calcium carbonate with carbon dioxide and one or more acids, the use of the surface-reacted natural calcium carbonate for the removal of endocrine disrupting compounds, as well as to a combination of a surface-reacted natural calcium carbonate and activated carbon for the removal of endocrine disrupting compounds. 
Postupak za uklanjanje spojeva endokrine razgradnje (SER-ova) iz vodenog medija, gdje se površinski reaktivni prirodni kalcijev karbonat ili vodena suspenzija koja sadrži površinski reaktivni kalcijev karbonat i ima pH veći od 6,0 mjereno na 20°C, dovodi u kontakt s medijem koji sadrži SER-ove, gdje je površinski reaktivni kalcijev karbonat proizvod reakcije prirodnog kalcijevog karbonata s ugljičnim dioksidom i jedne ili više kiselina, gdje se ugljični dioksid formira in situ tretmanom s kiselinom i/ili se dovodi iz nekog vanjskog izvora.
The present invention relates to method of transmitting and receiving signal and apparatus thereof. In one aspect of the present invention, the method of receiving a signal, includes receiving a signal transmitted from a specific radio frequency (RF) channel, demodulating the received signal, parsing a signal frame of the demodulated signal and obtaining a physical layer pipe (PLP) located in a layer-1 information region of a second pilot signal, from the signal frame. 
Postupak prijenosa emitiranja okvira signala digitalne televizije, DTV, naznačen time, što se sastoji od: generiranja (S531) sloja-1 informacije, sloj-1 informacije je fizički parametar za signalizaciju voda na fizičkom sloju, PLP, isporukom servisnog toka; izgradnje (S533) okvira signala koji se sastoji od korisnih sadržaja i uvoda, uvod obuhvaća prvi pilot signal koji prethodi drugom pilot signalu, drugi pilot signal uključuje sloj-1 informacije u čemu PLP je uključen u korisne sadržaje i drugi pilot signal, iprijenosa okvira signala putem najmanje jedne radio frekvencije, RF, kanala.
An aqueous pharmaceutical suspension, having a pH about 4.25 to about 9.43 adjusted by a buffer system, comprising, by weight/volume (g/100 mL), about 0.03% to about 4.80% of fexofenadine zwitterionic dihydrate Form I of formula (I) having a particle size of less than about 280 µm for at least about 90% of the fexofenadine zwitterionic dihydrate Form I; about 0.01% to about 020% of a wetting agent; 
Vodena farmaceutska suspenzija, naznačena time što ima pH od otprilike 4,25 do otprilike 9,43 a podešen je puferskim sustavom, koja sadrži, težinski/volumno (g/100 ml), otprilike 0,03 % do otprilike 4,80 % dvojnoionskog dihidratnog Oblika I feksofenadina formule (I), veličine čestica manje od otprilike 280 mm za najmanje otprilike 90 % dvojnoionskog dihidratnog Oblika I feksofenadina;
a sweetener system comprising, about 5% to about 40% of sucrose or invert sucrose; and 
sustav sladila, koji sadrži otprilike 5 % do otprilike 40 % saharoze ili invertne saharoze; i
% to about 40% of xylitol, sorbitol or sorbitol solution, or maltitol solution; 
% do otprilike 40 % ksilitola, sorbitola ili otopine sorbitola ili otopine maltitola;
The aqueous pharmaceutical suspension according to claim 1, wherein the particle size is less than about 50 µm for at least about 90% of the fexofenadine zwitterionic dihydrate Form 1. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 1, naznačena time što veličina čestica je manja od otprilike 50 mm za najmanje otprilike 90 % dvojnoionskog dihidratnog Oblika I feksofenadina.
The aqueous pharmaceutical suspension according to claim 1, wherein the particle size is less than about 40 µm for at least about 90% of the fexofenadine zwitterionic dihydrate Form I. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 1, naznačena time što veličina čestica je manja od otprilike 40 mm za najmanje otprilike 90 % dvojnoionskog dihidratnog Oblika I feksofenadina.
The aqueous pharmaceutical suspension according to claim 7, wherein, the fexofenadine zwitterionic dihydrate Form I is, by weight/volume (g/100 mL), about 0.60%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što dvojnoionski dihidratni Oblik I feksofenadina iznosi, težinski/volumno (g/100 ml), otprilike 0,60 %.
The aqueous pharmaceutical suspension according to claim 7, wherein the wetting agent is, by weight/volume (g/100 mL), about 0.02% to about 0.05%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što sredstvo za vlaženje iznosi, težinski/volumno (g/100 ml), otprilike 0,02 % do otprilike 0,05 %.
The aqueous pharmaceutical suspension according to claim 7, wherein the hydrocolloid gum is, by weight/volume (g/100 mL), about 0.35% to about 0.45%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što hidrokoloidna guma iznosi, težinski/volumno (g/100 ml), otprilike 0,35 % do otprilike 0,45 %.
The aqueous pharmaceutical suspension according to claim 7, wherein the hydroxyethylcellulose is, by weight/volume (g/100 mL), about 0.2% to about 0.3%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što hidroksietilceluloza iznosi, težinski/volumno (g/100 ml), otprilike 0,2 % do otprilike 0,3 %.
The aqueous pharmaceutical suspension according to claim 7, wherein the sucrose or invert sucrose is, by weight/volume (g/100 mL), about 10% to about 40%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što saharoza ili invertna saharoza iznosi, težinski/volumno (g/100 ml), otprilike 10 % do otprilike 40 %.
The aqueous pharmaceutical suspension according to claim 7, wherein the sucrose or invert sucrose is, by weight/volume (g/100 mL), about 20%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što saharoza ili invertna saharoza iznosi, težinski/volumno (g/100 ml), otprilike 20 %.
The aqueous pharmaceutical suspension according to- claim 7, wherein the sweetener system comprises xylitol and sucrose. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što sustav sladila sadrži ksilitol i saharozu.